Melatonin inhibits matrix metalloproteinase-9 activity by binding to its active site

Journal of Pineal Research

Volumn 54, Issue 4, 2013, Pages 398-405

  Rudra, Deep Sankar ^a   Pal, Uttam ^a   Maiti, Nakul Chandra ^a   Reiter, Russel J ^b   Swarnakar, Snehasikta ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Inhibitor; Matrix metalloproteinase 9; Melatonin

Indexed keywords

ALANINE; GELATINASE B; HISTIDINE; MELATONIN; PROLINE; ZINC;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; THERMODYNAMICS; TIME; ZYMOGRAPHY;

INHIBITOR; MATRIX METALLOPROTEINASE-9; MELATONIN;

CATALYTIC DOMAIN; CELL LINE, TUMOR; HUMANS; MATRIX METALLOPROTEINASE 9; MELATONIN; MODELS, MOLECULAR; PROTEASE INHIBITORS; PROTEIN BINDING; THERMODYNAMICS;

EID: 84879459578     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12034     Document Type: Article

References (54)

1. NAGASE H, WOESSNER JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
2. MASSOVA I, KOTRA LP, FRIDMAN R et al. Matrix metalloproteinases: structures, evolution, and diversification. Faseb J 1998; 12:1075-1095.
3. MORGUNOVA E, TUUTTILA A, BERGMANN U et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999; 284:1667-1670.
4. SCHECHTER. Reprint of "on the size of the active site in proteases. I. Papain". Biochem Biophys Res Commun 2012; 425:497-502.
5. AMOUR A, KNIGHT CG, WEBSTER A et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473:275-279.
6. KASHIWAGI M, TORTORELLA M, NAGASE H et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276:12501-12504.
7. D'ALESSIO S, FERRARI G, CINNANTE K et al. Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem 2008; 283:87-99.
8. SOUNNI NE, ROZANOV DV, REMACLE AG et al. Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int J Cancer 2010; 126:1067-1078.
9. OPDENAKKER G, Van Den STEEN PE, Van DAMME J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22:571-579.
10. OPDENAKKER G, Van Den STEEN PE, DUBOIS B et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukocyte Biol 2001; 69:851-859.
11. FRIDMAN R, TOTH M, CHVYRKOVA I et al. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metast Rev 2003; 22:153-166.
12. RAMOS-DESIMONE N, HAHN-DANTONA E, SIPLEY J et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274:13066-13076.
13. VU TH, SHIPLEY JM, BERGERS G et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93:411-422.
14. JOHNSON C, SUNG HJ, LESSNER SM et al. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues - Potential role in capillary branching. Circ Res 2004; 94:262-268.
15. LARSEN PH, WELLS JE, STALLCUP WB et al. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003; 23:11127-11135.
16. RAM M, SHERER Y, SHOENFELD Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26:299-307.
17. ROHDE LE, DUCHARME A, ARROYO LH et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99:3063-3070.
18. SELLNER J, LEIB SLIn bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis 2006; 21:647-656.
19. STARCKX S, Van Den STEEN PE, VERBEEK R et al. A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J Neuroimmunol 2003; 141:47-57.
20. Van Den STEEN PE, DUBOIS B, NELISSEN I et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol 2002; 37:375-536.
21. EGEBLAD M, WERB ZNew functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
22. LURLARO M, LOVERRO G, VACCA A et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999; 29:793-801.
23. BERGERS G, BREKKEN R, MCMAHON G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-744.
24. ACUFF HB, CARTER KJ, FINGLETON B et al. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res 2006; 66:259-266.
25. ZUCKER S, LYSIK RM, ZARRABI MH et al. Mr 92,000 type-IV collagenase is increased in plasma of patients with colon cancer and breast-cancer. Cancer Res 1993; 53:140-146.
26. BROWN PD. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 1998; 52:125-136.
27. RASMUSSEN HS, MCCANN PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75:69-75.
28. TOCHOWICZ A, MASKOS K, HUBER R et al. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible arg424 side-chain to selectivity. J Mol Biol 2007; 371:989-1006.
29. GANGULY K, KUNDU P, BANERJEE A et al. Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic Biol Med 2006; 41:911-925.
30. MISHRA A, PAUL S, SWARNAKAR S. Downregulation of matrix metalloproteinase-9 by melatonin during prevention of alcohol-induced liver injury in mice. Biochimie 2011; 93:854-866.
31. BARRETT P, BOLBOREA M. Molecular pathways involved in seasonal body weight and reproductive responses governed by melatonin. J Pineal Res 2012; 52:376-388.
32. HARDELAND R, MADRID JA, TAN DX et al. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012; 52:139-166.
33. MOTILVA V, GARCIA-MAURINO S, TALERO E et al. New paradigms in chronic intestinal inflammation and colon cancer: role of melatonin. J Pineal Res 2011; 51:44-60.
34. CARRILLO-VICO A, GUERRERO JM, LARDONE PJ et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27:189-200.
35. GALANO A, TAN DX, REITER RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
36. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
37. TAN DX, REITER RJ, MANCHESTER LC et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-197.
38. MISHRA A, BHATTACHARYA P, PAUL S et al. An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. Lung India 2011; 28:174-179.
39. FRIDMAN R, FUERST TR, BIRD RE et al. Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem 1992; 267:15398-15405.
40. BRADFORD MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
41. KUNDU P, MUKHOPADHYAY AK, PATRA R et al. Cag pathogenicity island-independent up-regulation of matrix metalloproteinases-9 and -2 secretion and expression in mice by Helicobacter pylori infection. J Biol Chem 2006; 281:34651-34662.
42. SAGHATELIAN A, JESSANI N, JOSEPH A et al. Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A 2004; 101:10000-10005.
43. MORRIS GM, HUEY R, LINDSTROM W et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009; 30:2785-2791.
44. SANNER MF. Python: a programming language for software integration and development. J Mol Graph Model 1999; 17:57-61.
45. GERSTEIN M. A resolution-sensitive procedure for comparing protein surfaces and its application to the comparison of antigen-combining sites. Acta Crystallogr A 1992; 48:271-276.
46. SWARNAKAR S, PAUL S, SINGH LP et al. Matrix metalloproteinases in health and disease: regulation by melatonin. J Pineal Res 2011; 50:8-20.
47. BROWN S, BERNARDO MM, LI ZH et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000; 122:6799-6800.
48. HONG RT, XU JM, MEI Q. Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2009; 15:1452-1458.
49. HU SL, YIN S, JIANG XD et al. Melatonin protects against alcoholic liver injury by attenuating oxidative stress, inflammatory response, and apoptosis. Eur J Pharmacol 2009; 616:287-292.
50. ESPOSITO E, MAZZON E, RICCARDI L et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008; 45:166-173.
51. PAUL S, BHATTACHARYA P, Das MAHAPATRA P et al. Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic pathway. J Pineal Res 2010; 49:156-168.
52. SWARNAKAR S, MISHRA A, GANGULY K et al. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J Pineal Res 2007; 43:56-64.
53. De GROOT AS, ARDITO M, MOISE L et al. Immunogenic consensus sequence T helper epitopes for a pan-Burkholderia biodefense vaccine. Immunome Res 2011; 7:7.
54. SAALAU-BETHELL SM, WOODHEAD AJ, CHESSARI G et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 2012; 8:920-925.